Schering Corporation

Merck Sharp + Dohme Corp.

Dnax Research Institute of Molecular and Cellular Biology, Inc.

Donna M. Rennick

Robert L. Coffman

Donna M Rennick

Robert A Kastelein

Rene De Waal Malefyt

Frank D Lee

Ken-ichi Arai

Takashi Yokota

Timothy R Mosmann

J Fernando Bazan

Jacqueline C Timans

Stefan Karl-Heinz Pflanz

Jeanne Cheung

Satwant K Narula

Birgit Oppmann

Sergio A Lira

Maria T Wiekowski

Sandra M Zurawski

Stephen D Hurst

Albert Zlotnik

Robert L Coffman

Joseph A Hedrick

Susan A Hudak

Purified genes encoding a cytokine or composite cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided.

Binding compounds for IL-27

IL-D80 polynucleotides

IL-D80 polypeptides and IL-27

Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.

IL-12P40 and IL-B30 polypeptide complex

Mammalian cytokines; related reagents

Use of the cytokine designated IL-174 to treat infectious diseases such as helminth infections.

Uses of IL-174 for treating helminth infections

Mammalian genes; related reagents and methods

Mammalian cytokines; related reagents and methods

Agonists or antagonists of cytokine designated IL-174, and various methods of their use are provided. In particular, the methods make use of facts that many activities of the IL-174 cytokine are described.

Methods of modulating IL-174 response

This invention relates to the use of lymphotactin or lymphotactin antagonists for administration to an animal. The administration of these therapeutic entities will attract certain cell types, or can be blocked to prevent such attraction. It also provides means to protect stem cells.

Lymphotactin uses

Mammalian proteins and muteins thereof, designated interleukin-4s (IL-4s), are provided which exhibit both B cell growth factor activity and T cell growth factor activity. Compounds of the invention include native human and murine IL-4s, muteins thereof, and nucleic acids which are effectively homologous to disclosed cDNAs, and/or which are capable of coding for mammalian IL-4s and their muteins.

Nucleic acids encoding human interleukin-4

A method of treating rheumatoid arthritis comprising administering human Interleukin-4 (IL-4) to an individual afflicted with the disease. The IL-4 is administered with a pharmaceutically acceptable carrier in a dose ranging from 1 .mu.g to 100 mg.

Use of interleukin-4 (IL-4) to treat rheumatoid arthritis

Fused polypeptides comprising interleukin-4 polypeptide fragments

A pharmaceutical composition comprising human Interleukin-4 (IL-4).

Pharmaceutical compositions comprising human interleukin-4 (IL-4)

Growing community of inventors

Los Altos, CA, United States of America

Donna M Rennick